Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 21, 2007; 13(31): 4168-4176
Published online Aug 21, 2007. doi: 10.3748/wjg.v13.i31.4168
Published online Aug 21, 2007. doi: 10.3748/wjg.v13.i31.4168
Table 1 Factors impeding our understanding of HCV issues world-wide
| Societal attitudes to the infected community |
| Injecting drug use is seen as a moral weakness and thus not needing to be addressed |
| Infection is the fault of the infected individual |
| Why should society expend money on those who undertake illicit activities? |
| Societal attitudes to prisoners |
| Prisoners are imprisoned to be punished |
| Prison sentences are usually relatively brief so the prisoner can wait for assessment and treatment |
| Drugs are not available in prison so there is no need for prevention measures against HCV |
| Societal attitudes affect Health care worker attitudes |
| More discrimination against HCV infected individuals occurs in health care settings than in the general community |
| Patients unwilling to disclose (their condition?) for fear of discrimination leading to poor care |
Table 2 Reducing the number of new HCV infections
| Actions that are required to achieve a reduction in new infections: |
| Acknowledging the existence of the epidemic |
| Overcoming denial of the pathogenicity of the HCV |
| Accepting that this disease is more prevalent than HIV |
| Defining the natural history more accurately |
| Increasing understanding of the biology of the HCV |
| Requires a greater funding base for research |
| Greater collaborative effort between clinical and research centres |
| Defining transmission risks accurately |
| Working with injecting user groups an essential requirement |
| Studies with the virus will allow a great expansion of knowledge |
| Responding to these risks adequately |
| Governments must commit to addressing the epidemic |
| Increasing access to treatment |
| Define clinical pathways |
| Optimise access to treatment for those with more severe disease |
| Advertise treatment efficacy more clearly |
| Improving treatment efficacy |
- Citation: Batey RG. Controversies in and challenges to our understanding of hepatitis C. World J Gastroenterol 2007; 13(31): 4168-4176
- URL: https://www.wjgnet.com/1007-9327/full/v13/i31/4168.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i31.4168
